DSC00818e web.jpg
Testing Information and Ordering
Clinical Test Catalog and Ordering Information

1. Contact our Client Services team via phone, email, or using the contact form on our site. Our representative will ask you for shipment information and send a specimen collection kit to your facility. 

2. Obtain the patient’s signature on Helomics’ Universal Informed Consent Form: UIC forms are available for download here and can also be requested from the Client Services representative processing your kit order.

3. Immediately following the patient’s surgery, follow the specimen submission instructions to secure the patient specimen in the collection kit and ship it to the Helomics lab. Include the completed requisition form found inside the kit and a patient face sheet, if available.

Specimen Acceptance Criteria
For all Helomics testing , all samples submitted to Helomics must be properly labeled with 2 unique patient identifiers to avoid rejection upon receipt.
Tumor Drug Response Testing

To play, press and hold the enter key. To stop, release the enter key.

  • Only provides results on confirmed gynecological tumors

  • Specimen must be fresh tissue shipped in 10% McCoy’s growth medium provided in Helomics’ standard Tumor Profiling Kits

  • Specimen cannot be exposed to a fixative (i.e. formalin, acetone, ethanol)

  • Specimen cannot be frozen

  • Specimen must have an extraction date that is ≤ 5 days post extraction

  • Pathology report or confirmed gynecological diagnosis from the ordering physician received for the submitted sample

  • Acceptable signature and date on the order form

  • Complete patient demographics and insurance

Genomic Biomarker Testing
  • Helomics provides two standard kit options for Genomic Testing samples:

    • Tumor Profiling Kit -Tissue specimens must be shipped in 10% neutral buffered formalin

    • FFPE Kit - Specimens must be shipped as slides or tissue blocks

  • Pathology report or confirmed diagnosis from the ordering physician received for the submitted sample

  • Acceptable signature and date on the order form

  • Complete patient demographics and insurance

Specimen Rejection Criteria
For All Helomics’ Products If any of the following criteria are met, then a specimen will be rejected and a Termination Report will be issued to the ordering physician.
  • If a specimen is not properly labeled

  • If a specimen arrives in an unacceptable medium

  • If the pathology criterion (origin, histology, stage) is not met or is inappropriate for the requested test

  • If a physician’s order is not completed and signed

  • If a patient’s demographics and insurance information is not received

Clients will be contacted as soon as possible for resolution if issues are identified.

Turnaround Times by Product
  • Tumor Drug Response Profiling: 28–35 days after receipt of the fresh tissue and all required paperwork; depending on the growth profile of the sample

  • Genomic Testing: 10–14 days after receipt of the order form and sample; Sample may arrive  prior to the order form, but testing will not begin until the order form is received 

Frequently Asked Questions
What is Tumor Drug Response Testing?

Drug Response profiling is a treatment selection marker. It determines how an individual gynecologic cancer patient is likely to respond the various types of chemotherapy by testing the treatment options on that patients live cancer cells and measuring cell response. This provides valuable insights that help guide physicians’ treatment decisions, giving you an edge against gynecologic cancer.

Why Tumor Drug Response Testing?

Your physician is using every advantage available to improve the odds in your fight against cancer. Drug Response Profiling is designed to reduce your risk of receiving therapies that are ineffective or to identify alternatives when the typical treatments recommended for your type of cancer cannot be tolerated.

What is Genomic Testing?

Genomic testing is a group of clinically relevant cancer-related biomarker tests that look to your genetics to predict your cancer’s response to various types of chemotherapy and/or the course your disease is likely to take. The biomarkers included in Genomic testing are well-validated and supported by current research and key opinion leaders.